U.S. Markets open in 8 hrs 31 mins
  • S&P Futures

    3,399.75
    +6.25 (+0.18%)
     
  • Dow Futures

    27,636.00
    +55.00 (+0.20%)
     
  • Nasdaq Futures

    11,505.50
    +13.25 (+0.12%)
     
  • Russell 2000 Futures

    1,607.10
    +5.00 (+0.31%)
     
  • Crude Oil

    38.77
    +0.21 (+0.54%)
     
  • Gold

    1,910.40
    +4.70 (+0.25%)
     
  • Silver

    24.59
    +0.17 (+0.70%)
     
  • EUR/USD

    1.1829
    +0.0015 (+0.1301%)
     
  • 10-Yr Bond

    0.8010
    0.0000 (0.00%)
     
  • Vix

    32.46
    +4.91 (+17.82%)
     
  • GBP/USD

    1.3034
    +0.0013 (+0.0978%)
     
  • USD/JPY

    104.7650
    -0.0700 (-0.0668%)
     
  • BTC-USD

    13,125.23
    +23.04 (+0.18%)
     
  • CMC Crypto 200

    261.71
    -1.71 (-0.65%)
     
  • FTSE 100

    5,792.01
    -68.27 (-1.16%)
     
  • Nikkei 225

    23,412.28
    -82.06 (-0.35%)
     

TaiGen filed US IND for its influenza antiviral TG-1000

·2 mins read

TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.

A Phase 1 trial for in China was initiated by TaiGen in July 2020 and has successfully completed the first 4 groups in the single ascending dose part. A Phase 2 protocol has also been submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing last month.

"We are excited about the IND filing in the US for the internally developed TG-1000 which has the potential to be a single dose treatment for influenza," said Kuo-Lung Huang, the Chairman and CEO of TaiGen, "TG-1000 IND filing demonstrates yet again TaiGen's capacity and experience in research and development of NCEs."

About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and market-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to TG-1000, TaiGen has three other in-house discovered NCEs: Taigexyn®, a novel non-fluorinated quinolone available in both oral and intravenous formulations, TG-3000, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, and Furaprevir, a HCV protease inhibitor for treatment of chronic hepatitis infection. Taigexyn® is already on the market in the mainland China and Taiwan, TG-3000 has completed Phase 2 clinical studies, and Furaprevir is currently in Phase 3 clinical development.

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/taigen-filed-us-ind-for-its-influenza-antiviral-tg-1000-301145272.html

SOURCE TaiGen